#USA #Atlanta #Clinical Trials #Alzamend Neuro #Ault Lending

Alzamend Neuro's Financial Milestone: Funding Announcement

Alzamend Neuro, Inc. (Nasdaq: ALZN), a promising clinical-stage biopharmaceutical company, has recently made waves in the medical community by announcing the initial closing of a Securities Purchase Agreement with Ault Lending, LLC. This significant partnership marks a crucial step in the company’s mission to develop innovative treatment options for serious mental health conditions including Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

On August 4, 2026, Alzamend revealed that it has secured an initial tranche of $7.5 million in gross proceeds from Ault Lending, which is part of a larger funding agreement amounting to $25 million in total. According to the agreement, Ault Lending has committed to purchasing up to 25,000 shares of Alzamend's newly designated Series D Convertible Preferred Stock at $1 million each. The purchase price is pegged at $1,050 per share, with plans for further tranche closings to follow.

The initial tranche consists of 7,500 Preferred Shares and additional funding is expected to arrive in subsequent months. The next closing, anticipated within ten business days, aims to secure another $2.5 million through the purchase of an additional 2,500 Preferred Shares. Following this, the remaining 15,000 Preferred Shares are set to be acquired monthly at a rate of $1 million each over approximately fifteen months, depending on standard closing conditions being met.

This funding will be pivotal for Alzamend, allowing the company to boost its working capital and continue advancing its clinical trial initiatives. A focus will be placed on furthering their Phase I/IIA safety, tolerability, and efficacy clinical trial of an innovative immunotherapeutic vaccine—a potential game-changer in the quest for an Alzheimer's cure.

Stephan Jackman, CEO of Alzamend, commented on the funding's importance, stating, "The funding from Ault Lending will help us further our clinical trials. We are working diligently towards completing the next milestone. If we can develop a next-generation lithium product that does not require therapeutic drug monitoring, it would constitute a major improvement over current lithium-based treatments."

The support from Ault Lending has personal significance to its Executive Chairman, Milton “Todd” Ault, III, who emphasized the mission's emotional resonance. He stated, "I have lost family members to Alzheimer's, and I have watched loved ones live with bipolar disorder, major depressive disorder, and PTSD. Backing Alzamend's continued clinical progress is exactly the kind of investment Ault Lending was built to make."

Alzamend's innovative pipeline includes two key drug candidates: AL001, which combines lithium with salicylate and L-proline to enhance delivery and safety, and ALZN002, an active-immunity vaccine designed to tackle Alzheimer’s by restoring the immune system's function. Both candidates are exclusively licensed from the University of South Florida Research Foundation, showcasing Alzamend's commitment to leveraging academic innovation for therapeutic advancements.

As a clinical-stage company, Alzamend Neuro remains focused on developing safe and effective treatments that could significantly improve the lives of millions afflicted with these challenging mental health conditions. This funding agreement may prove to be the catalyst they need to initiate broader clinical trials and bring new hope to patients, families, and communities affected by these disorders.

In conclusion, the partnership between Alzamend Neuro and Ault Lending symbolizes a promising investment into the future of mental health treatment. With funding firmly in place and innovative solutions on the horizon, Alzamend is poised for substantial growth and progress in the coming months.